F2RL1 and melanoma: PAR-2 expression has also been observed in cancers of the lungs [14], liver [15], prostate [11,16], thyroid [15], breast [15,17], gastrium [18-20], colon [21,7], pancreas [22,23], gallbladder [24], and melanoma [16] and glioblastoma [25].